Literature DB >> 15307570

The natural course of disease following HIV-1 infection in dar es salaam, Tanzania: a study among hotel workers relating clinical events to CD4 T-lymphocyte counts.

Muhammad Bakari1, Willy Urassa, Kisali Pallangyo, Andrew Swai, Fred Mhalu, Gunnel Biberfeld, Eric Sandström.   

Abstract

Current HIV management guidelines are based on natural history studies from the developed world. Data on the similarity of the natural course of HIV-1 infection conflict with studies in the developing world. A cohort of 1887 hotel workers with no access to antiretroviral therapy was followed between 1990 and 1998 in Dar es Salaam through annual clinical evaluations and CD4+ T-lymphocyte (CD4 cell) count determinations. 196 (10.4%) were HIV-1 sero-prevalents; 133 (7.9%) were HIV-1 sero-incidents; and 1558 (82.6%) remained HIV seronegative. Follow-up duration was 13,719 and 82,742 months for HIV-1 seropositives and HIV seronegatives respectively. Clinical events occurred at median CD4 cell counts similar to those previously reported from the developed world, but death occurred at higher counts. Off-duty last 6 months, chronic diarrhoea and a faster CD4 cell count decline were associated with faster disease progression and death. In Tanzania HIV natural history is similar to that from the developed world and similar management guidelines could be employed.

Entities:  

Mesh:

Year:  2004        PMID: 15307570     DOI: 10.1080/00365540410016249

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe.

Authors:  T B Hallett; S Gregson; S Dube; E S Mapfeka; O Mugurungi; G P Garnett
Journal:  Sex Transm Infect       Date:  2011-06-02       Impact factor: 3.519

2.  The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling.

Authors:  Timothy B Hallett; Simon Gregson; Sabada Dube; Geoff P Garnett
Journal:  PLoS Med       Date:  2008-03-11       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.